Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Sex-based differences in clinical outcomes among patients with obesity and heart failure with preserved ejection fraction treated with tirzepatide.
Journal: Therapeutic advances in cardiovascular disease
Published: August 17, 2026
Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure.
Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure.
Journal: Diabetes & vascular disease research
Published: July 09, 2026
Performance of Risk Scores in Predicting Right Ventricular Failure After LVAD Implantation.
Journal: Angiology
Published: May 21, 2026
Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Adults With Durable Left Ventricular Assist Devices: A Multicenter Retrospective Cohort Study.
Journal: American journal of therapeutics
Published: March 02, 2026
Association of Tirzepatide Use With Clinical Outcomes After TAVR in Obese Patients: A Propensity Score-Matched Real-World Study.
Journal: Journal of the Society for Cardiovascular Angiography & Interventions
Published: February 23, 2026
Differential Outcomes with Empagliflozin and Dapagliflozin in Heart Failure with Mildly Reduced Ejection Fraction.
Journal: medRxiv : the preprint server for health sciences
Published: February 06, 2026
Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study.
Journal: The American journal of cardiology
Published: February 02, 2026
Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study.
Journal: The American journal of cardiology
Published: February 02, 2026
Differential Outcomes With Empagliflozin and Dapagliflozin in Heart Failure With Mildly Reduced Ejection Fraction With and Without Diabetes Mellitus.
Journal: The American journal of cardiology
Published: January 23, 2026
Differential Outcomes With Empagliflozin and Dapagliflozin in Heart Failure With Mildly Reduced Ejection Fraction With and Without Diabetes Mellitus.
Journal: The American journal of cardiology
Published: January 23, 2026
Additive Cardiorenal Benefits of Finerenone and SGLT2 Inhibitor Combination Therapy in Diabetic CKD: A Propensity-Matched Real-World Study.
Journal: The American journal of cardiology
Published: January 01, 2026
Last Updated: 09/26/2026